Novel Surface Technologies for Genomics, Proteomics, and Drug Discovery

A Commercial Nonbinding Surface Effectively Reduces Fibrinogen Adsorption but Does Not Prevent Platelet Adhesion to Fibrinogen

“…According to data collected by the manufacturers, the nonbinding surface may profoundly reduce the binding of proteins, such as immunoglobulins G, bovine albumin, and insulin, and nucleic acids compared to native polystyrene. [ 16 ] The use of a nonbinding surface may also decrease the adsorption of small molecular drugs (below 15%); however, these results largely depend on the drug chemistry and are not always in line with expectations of researchers. [ 18,19 ] The literature contains no data on the behavior of blood platelets upon contact with the nonbinding surface, i.e., one of the fundamental tests for evaluating the clinical applicability of biomaterials.…”

“…[13,15] The commercially available nonbinding microplate can be regarded as a nonfouling surface, demonstrating low protein, peptide, DNA and RNA binding, and thus has good assay sensitivity. [16] Nonbinding surfaces are created by chemical treatment to produce a hydrophilic layer, which enables biomolecules to remain in solution, thereby preventing their binding to the surface. The stability of the nonbinding surface is not precisely defined, but it is sufficient for assays and short-term storage.…”

“…The stability of the nonbinding surface is not precisely defined, but it is sufficient for assays and short-term storage. [1] It has been estimated that the nonbinding microplate may substantially reduce adsorption of proteins (up to 2.5-5 ng immunoglobulin G (IgG), bovine albumin, or insulin per cm 2 that gives >95% binding reduction vs polystyrene) [16,17] and drugs. [18,19] However, the thrombogenic potential of the nonbinding surface, when it comes in contact with blood platelets, has not been studied so far.…”